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Abstract: The present study evaluated 17β-estradiol (17βE2) (2.5 mg/kg sc) effects on bilateral 
OBX-induced behavioral changes and oxidative stress. OBX in male Wistar rats produced an 
increase in lipid peroxidation products and a decline in reduced glutathione (GSH) content 
and glutathione peroxidase (GSH-Px) activity, together with an increase in caspase-3 activity. 
Additionally, OBX triggered changes of behavior such as an enhancement of immobility time 
in the forced swim test and hyperactivity in the open ﬁ  eld test. These changes were reversed by 
treatment with 17βE2 (14 days). Our results reveled that 17βE2 has a protective effect against 
oxidative stress, cell damage and behavioral changes induced by OBX, and present antidepres-
sant and antianxiety properties.
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Introduction
Among models of depression have been described, the olfactory bulbectomy (OBX) 
rat is among well validated animal models that exhibit a number of behavioral, neu-
roendocrine and neurochemical changes with great relevance to clinical depression 
(Song and Leonard 2005). OBX results in degeneration of many areas such as the 
cortex, hippocampus, amygdale, locus coeruleus, and dorsal raphe nuclei, and pro-
duces enlargement of the lateral and third ventricules. The degenerative changes in 
the amygadala, hippocampus, and cortex induce in turn alterations in memory and 
behavior as well as cognitive deﬁ  cits. Additionally OBX triggers a reduction in the 
number of synapses and the levels of brain noradrenaline and serotonin while the levels 
of glutamate are increased. OBX also triggers hyperactivity of the central cholinergic 
system and enhanced GABA turnover (Song and Leonard 2005). These changes may 
be reversed by chronic, but not acute, antidepressant treatments (Harkin et al 2003; van 
der Stelt et al 2005). It is therefore an attractive proposition to study pathophysiology 
of depression as well as to assay the effects of different antidepressive drugs.
The World Health Organization predicts that depression will be the second cause 
of loss in human disability-adjusted life years worldwide (Nowak et al 2003; Akiskal 
2005). Affective disorders, especially major depression, are the most common psycho-
logical disorders affecting 10% of all patients seeking treatment at primary healthcare 
facilities worldwide (Murray and Lopez 1997). Major depression is a heterogeneous 
disorder. The classiﬁ  cation is based on a cluster of symptoms described by the Diag-
nostic and Statistic Manual of Mental Disorders (DSM-IV) (APA 1994).
Women have higher rates of depression than men (Weismann and Klerman 1977) with 
this disorder affecting approximately twice as many women as men. Additionally, epide-
miological and clinical studies have reported that the perimenopause in women is associ-
ated with an increased vulnerability to depression. Thus, estrogen replacement therapy Neuropsychiatric Disease and Treatment 2008:4(2) 442
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has been proposed as a potentially effective treatment for mood 
disorders occurring in this period (Rasgon et al 2002).
Estrogens have been proved potent neuroprotective and 
antioxidant agents. The female sex hormone 17β-estradiol 
(17βE2) has shown cytoprotective activities in animal models 
of neurodegeneration. A recent study of our group found that 
sex ovarian hormone has a neuroprotective effect against 
the changes induced by ovariectomy and ovariectomy plus 
3-nitropropionic acid (Túnez et al 2006).
On the other hand, the studies of Fernández-Guasti and 
colleagues have shown that sex hormones estradiol and testos-
terone show antidepressant- and anxiolytic-like action in rats 
(Martínez-Mota et al 2000; Fernandez-Guasti and Martínez-
Mota 2005; Estrada-Camarena et al 2006). In addition, a recent 
work by this group has found that estrogens participate in the 
antidepressant-like effect of desipramine and ﬂ  uoxetine in the 
forced swimming test (Martinez-Mota et al 2008). Walf and 
Frye (2005, 2007a) have observed a similar effect of estro-
gen treatment. They have also recently shown that estradiol 
enhanced the spatial learning ability of rats (Frye et al 2007).
Based on this evidence, we designed the current study 
to test our working hypothesis that 17βE2 administration 
may result in an improvement in the oxidative stress bio-
markers, caspase-3 activity, and OBX-induced behavioral 
changes.
Materials and methods
Chemical reagents and administered 
products
17βE2 and all other chemicals were purchased from Sigma 
Aldrich Co., Ltd. (St. Louis, MO, USA).
Animals
Male rats of the Wistar strain (purchased from Charles River, 
Barcelona, Spain) weighing 220–250 g were used throughout 
all experiments. For at least 1 week prior to experiments, 
the rats were housed ﬁ  ve to a cage at a constant temperature 
(20–23 °C), illumination (12-h light/12-h dark cycle, light 
on at 08:00 h) and were provided with food (Purine®, Bar-
celona, Spain) and water ad libitum. All animals welfare 
and procedures were in accordance with the European 
Communities Council Directive of 24 November 1986 
(86/609/ECC) and RD 223/1988, and were approved by the 
University of Cordoba’s Bioethics Committee, Spain.
To carry out this study, 25 rats were used. These rats were 
divided into ﬁ  ve groups as follows: i) control; ii) treated with 
17βE2; iii) sham operated; iv) olfactory bulbectomy (OBX); 
and v) OBX+17βE2.
Surgical procedure and drug treatment
Surgery took place 1 week after arrival of the animals in the 
laboratory. Bilateral olfactory bulbectomy was performed 
with rats anesthetized under ketamine (50 mg/kg/i.p.; Keto-
lar®, Pﬁ  zer S.A., Madrid, Spain). The top the skull was shaved 
and swabbed with an antiseptic, after which a midline frontal 
incision was made in the scalp and the skin was retracted 
bilaterally. Burr holes (2 mm) were drilled into the skull at 
the points 7 mm anterior to bregma and 2 mm lateral to the 
bregma suture, after which the olfactory bulbs were severed 
from the frontal cortex, removed and skin was closed with 
surgical clips. Sham operated animals underwent the same 
procedure except for excision and removed of the olfactory 
bulbs. The rats, housed ﬁ  ve per cage, were given 2 weeks to 
recover from the surgical procedure and develop the OBX 
syndrome prior to drug administration. They were handled 
daily throughout the recovery period to eliminate any aggres-
siveness that would otherwise arise, because the degree of 
irritability depends on the degree of handling following 
surgery (Leonard and Tuite 1981). Drug treatment began two 
weeks after surgery. 17βE2 was administered chronically once 
daily for 14 days at a dose of 2.5 mg/kg body weight s.c.; the 
doses of estradiol used was selected on the bases of previous 
our reports demonstrating in vivo neuronal protection and 
reduction of oxidative stress (Muñoz-Castañeda et al 2005; 
Túnez et al 2006). 24 h after last treatment and under anes-
thetic with ether, the animals were sacriﬁ  ced by decapitation 
and their brain were rapidly removed, frozen on dry ice, and 
stored frozen (−40 °C) until assayed.
Biochemical parameters evaluated
Lipid peroxidation (LPO) products
The LPO levels (malondialdehyde + 4-hydroxyalkenals; 
MDA+4-HDA) were evaluated in brain homogenates. 
They have been used an indicator of lipid peroxidation. 
Lipid peroxidation is a mechanism of cellular injury. The 
levels of lipid peroxidation products were determined using 
reagents purchase from Oxis International (LPO-586 kit; 
Oxis International, Portland, OR, USA). Brain tissue were 
homogenized in ice-cold buffer (20 mM Tris-HCl) and 
they was then centrifuged at 10,000 × g for 10 min at 4 
°C. the supernatant was collected and immediately tested 
for LPO. The kit uses a chromatogenic reagent which 
reacts with the LPO (MDA+4-HDA). The content of LPO 
is expressed as LPO nanomol per milligram of protein 
(nmol/mg protein), and absorbance was evaluated in a 
specgtrophotometer (UV-1603 Shimadzu, Kyoto, Japan) 
at wavelength 586 nm.Neuropsychiatric Disease and Treatment 2008:4(2) 443
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Reduced glutathione (GSH) levels
GSH plays an important role as a co-enzyme in different 
enzymes. This tripeptide present a relevant function in anti-
oxidant system. The levels of GSH were estimated using 
reagents purchased from Oxis International (Portland, OR, 
USA), ie, GSH-400 kits. The content of GSH is expressed as 
GSH nanomol per milligram of protein (nmol/mg protein), 
and absorbance was evaluated in a specgtrophotometer (UV-
1603 Shimadzu, Kyoto, Japan) at wavelength 420 nm.
Glutathione peroxidase (GSH-Px) activity
GSH-Px (EC, 1.11.1.9) is an enzyme whose function is to 
detoxify peroxides in the cell. Its activity was evaluated 
by the Flohé and Gunzler method (1984). The tissues were 
homogened in ice-cold buffer (0.1M KH2PO4/K2HPO4, pH 
7.0 plus 29.2 mg EDTA in 100 ml of distilled water and 
10.0 mg digitonin in 100 ml of distilled water, ﬁ  nal volume, 
2000 ml) to produce a homogenate. The homogenates were 
then centrifuged at 10,000 × g for 10 min at 4 °C. The GSH-Px 
assay is based on the oxidation of NADPH to NAD+, catalyzed 
by a limiting concentration of glutathione reductase, with 
maximum abasorbance at 340 nm. The activity of GSH-Px 
is expressed as units per milligram of protein (U/mg protein), 
and absorbance was evaluated in a spectrophotometer 
(UV-1603 Shimadzu, Kyoto, Japan).
Total superoxide dismutase (SOD) activity
SOD (E.C.: 1.15.1.1) is an enzyme which catalyzes the 
dismutation superoxide ion into oxygen and hydrogen 
peroxide. Its activity was assayed by Sun and colleagues 
(1998). Brain tissue was homogenized in ice cold isotonic 
saline. The homogenates were then centrifuged at 10,000 × g 
for 10 min at 4 °C. SOD assay is based on the ability of 
SOD to inhibit the reduction of nitroblue tetrazolium (NBT) 
reduction by superoxide generator. The activity of GSH-Px is 
expressed as units per milligram of protein (U/mg protein), 
and absorbance was evaluated in a spectrophotometer (UV-
1603 Shimadzu, Kyoto, Japan) with maximum at 560 nm.
LDH activity
The assay is based on measurement of activity of lactate 
dehydrogenase (LDH) which is a stable enzyme normally 
found in the cytosol of all cells. LDH in the striatal homog-
enate were assayd using kit purchased from BioVision Inc. 
(Mountain View, CA, USA), ie, LDH-Cytotoxicity assay kit. 
The activity of LDH is expressed as units per milligram of 
protein (U/mg protein), and absorbance was evaluated in a 
spectrophotometer (UV-1603 Shimadzu, Kyoto, Japan) with 
maximum absorbance at 500 nm.
Caspase-3 activity
The caspase-3 activity in the brain homogenates were mea-
sured using reagents purchased from BioVision Inc. (Moun-
tain View, CA, USA), ie, Caspase-3/CPP32 colorimetric 
assay kit. The activity is expressed as optical density arbitrary 
units per milligram of protein (O.D. arbitraty units/mg pro-
tein), and absorbance was evaluated in a spectrophotometer 
(UV-1603 shimadzu, Kyoto, Japan) at wavelength 405 nm.
Protein estimation
The protein concentration was determined by the Bradford 
method (1976) using kit purchased from Sigma Aldrich Co., 
Ltd. (St. Louis, MO, USA), ie, Bradford reagents B6916 assay 
kit. The absorbance was evaluated in a spectrophotometer 
(V-1603 Shimadzu, Kyoto, Japan) at wavelength 595 nm, 
using bovine serum albumin as a standard.
Open ﬁ  eld test (OFT; anxiety)
All rats (control and OBX treated or not with 17βE2) were 
subjected to an open ﬁ  eld test on the 14th day of chronic 
17βE2 administration. Each rat was placed individually 
into the center of the open ﬁ  eld apparatus. The open ﬁ  eld 
apparatus was a circle made of wood, 90-cm in diameter. 
The test was performed between 09:00 and 12:00 h. A 60 W 
light bulb was positioned 90–100 cm above the center, 
and provided the only source of illumination in the testing 
room. Each animal was place in the center of the open ﬁ  eld 
apparatus, and the ambulation scores (the number of squares 
crossed) were measured during a 3-min period (Nowak et al 
2003; Xu et al 2005).
Forced swim test (FST; depressive)
This study was carried out in rats according to the methods 
describe by Porsolt and colleagues (1978). The rats were 
placed, after the open ﬁ  eld test, in Plexiglas cylinders 
(height: 40 cm, diameter: 18 cm) containing 25 cm water, 
maintained at 23–25°C. After 15 min in the water, they 
were removed and allowed to dry 15 min in a heated con-
tainer before being returned to their home cages. They were 
replaced in the cylinders 24 h later and the total duration 
of immobility was measured during a 5-min test. A rat was 
judged to be immobile when it remained ﬂ  oating passively 
in the water.
Statistical analysis
Statistical analysis of the data was accomplished by means 
of the SPSS® statistical software package (SPSS Iberica, 
Madrid, Spain). The Shapiro-Wilk test did not show a Neuropsychiatric Disease and Treatment 2008:4(2) 444
Tasset et al
signiﬁ  cant departure from normality in the distribution of 
variance values. To evaluate variations in data, a one-way 
analysis of variance (one-way ANOVA) was corrected with 
the Bonferroni test. The level of statistical signiﬁ  cance was 
set at p  0.05. All results are expressed as mean ± SD.
Results
Effects of OBX and 17βE2 on behavior
The administration of estrogen to healthy animals did not 
prompt changes in the behavioral parameters evaluated in the 
present work. OBX produced a signiﬁ  cant increase of immo-
bility time and ambulation counts (immobility: 90.20 ± 4.32 
seconds in the control group vs 160.40 ± 10.84 seconds 
in the OBX group, p  0.001; ambulation:15.60 ± 0.25 
counts in the control group vs 30.40 ± 1.33 counts in the 
OBX group p  0.001) (Figure 1). Bulbectomised rats 
that were given chronic 17βE2 administration for 14 days 
(OVX+17βE2) exhibited a signiﬁ  cant reduction of immo-
bility time in the FST (73.80 ± 0.80 seconds, ie, 53.99 % 
reduction) and hyperactivity in OFT (23.00 ± 1.14 counts, 
ie, 24.34 % reduction), compared with the OBX-group 
(Figure 1).
Effects of OBX and 17βE2 on oxidative 
stress and cell damage biomarkers
OBX signiﬁ  cantly increased lipid peroxidation products in 
brain tissue (Table 1). Additionally, OBX-rat showed a reduc-
tion in GSH content, GSH-Px and SOD activities (Table 1). 
OBX-induced changes on oxidative stress biomarkers were 
reversed toward normality by chronic administration of 17βE2 
whereas none of these parameters were affected in control 
animals. LDH and caspase-3 were used as an indicator of 
cell damage. Removal of olfactory bulbs in rats did not affect 
LDH activity (Figure 2), whereas caspase-3 activity was 
signiﬁ  cantly enhanced (0.26 ± 0.004 OD arbitrary units/mg 
protein in control group vs 0.37 ± 0.004 OD arbitrary units/
mg protein in OBX group, p  0.001) (Figure 2). Admin-
istration of 17βE2 reversed caspase-3 activation induced by 
OBX (0.37 ± 0.004 OD arbitrary units/mg protein in OBX 
group vs 0.25 ± 0.004 OD arbitrary units/mg protein in an 
OBX+17βE2 group, p  0.001) (Figure 2).
Discussion
Several studies investigating the role that gonadal hormones 
play in relation to animal models of depression show contra-
dictory results (Kennett et al 1986; Bernardi et al 1989, 1990). 
OBX triggers immunological, behavioral, neurochemical, 
and hormonal alterations that resemble the changes observed 
during major depressive disorder (Song and Leonard 1995, 
2005). In the present study, we have demonstrated that OBX 
prompts changes in behavior, oxidative stress, and caspase-3 
activation, similar to those observed during major depres-
sion. Importantly, we have shown that 17βE2 administration 
is able to reverse these OBX-induced changes, acting as an 
antidepressant and antioxidant agent.
It is well known that free radicals and other reactive spe-
cies are involved in various physiological and pathological 
conditions, including aging. They have also been implicated 
in the pathophysiology of neuropsychiatric disorders such as 
mood alterations, both in human and experimental models 
(Khanzode et al 2003; Eren et al 2007; McIntyre et al 2007; 
Zaﬁ  r and Banu 2007). Additionally, numerous studies have 
shown that reactive oxygen species (ROS) play a relevant 
role in the pathophysiology of depression (Bilici et al 2001; 
Atmaca et al 2004).
Our results show that bilateral bulbectomy triggers an 
oxidative stress state characterized by decreased antioxidant 
capacity and increased levels of lipid peroxidation products. 
ROS generated by OBX signiﬁ  cantly compromise the in vivo 
antioxidant defenses of the animals. These data are in accor-
dance with a previous study of our group which established 
that OBX causes a high increase in lipid peroxidation 
products, with a concomitant decline in the antioxidant 
defenses (Túnez et al 2007a). Furthermore, our results indi-
rectly agree with data of clinical studies which observed a 
correlation between mood disorders and oxidative stress 
(Forlenza and Miller 2006; Vawter et al 2006; McIntyre et al 
2007).Moreover, we have found that chronic 17βE2 adminis-
tration to bulbectomised animals resulted in enhancement of 
the rat antioxidant status, protecting them against oxidative 
damage. This effect is in agreement with previous studies 
which show cytoprotective and antioxidative action of 17βE2 
in cell and animal models of neurodegenerative diseases 
(Mattson et al 1997; Feng et al 2005; Simpkins et al 2005; 
Túnez et al 2006; Tripanichkul et al 2007) and, indirectly, 
with reports which indicate that estrogen deﬁ  ciency as a 
result of ovariectomy induced severe brain oxidative damage 
(Kume-Kick et al 1996; Túnez et al 2006, 2007b). Addition-
ally, our results are partly supported by studies which have 
found that antidepressant drugs provide protection against 
oxidative stress (Eren et al 2007; Túnez et al 2007a; Zaﬁ  r and 
Banu 2007). Thus, our data show that 17βE2 treatment can 
reduce oxidative stress generated by OBX. This antioxidative 
response may account, at least partially, for the beneﬁ  cial 
effect of 17βE2 in this model.Neuropsychiatric Disease and Treatment 2008:4(2) 445
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Figure 1 The effects of chronic 17βE2 administration on the ambulation in open ﬁ  eld test (panel A) and immobility time in forced swim test in the olfactory bulbectomy (OBX) 
model (panel B) of depression in rats. The ambulation scores was evaluated as the number of squares crossed during a 3-min period the open ﬁ  eld sessions. The immobility time 
was recorded during a 5-min period the swim sessions. Each value represents mean ± SD; n = 5 animals per group. ap  0.001 versus control; bp  0.001 versus OBX.
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It is possible that enhanced free radicals generation can 
overwhelm cell antioxidant defense systems and triggered a 
pathogenic cascade which leads to cell death. Interestingly, 
OBX did not enhance LDH levels, whereas it prompted 
changes in caspase-3 activity, data which indicate that OBX 
may be induced cell damage. These data are in concordance 
with other studies which suggest that olfactory bulbs removal 
prompts the cell damage (Carrr and Farbmen al 1992; Michel 
et al 1994; Túnez et al 2007a). Moreover, in the present 
study we found that 17βE2 prevents cell damage induced 
by OBX. According to our data, other studies have shown 
that estrogen treatment may prevent apoptosis, a cellular 
pathway that involves to caspase-3 activity (Monroe et al 
2002; Rau et al 2003; Túnez et al 2006; Gerstner et al 2007; 
Satoh et al 2007).
Additionally, our study evaluated the antidepressant 
effect of 17βE2 on rats showing behavioral changes as 
a result of OBX. These changes included an increase of 
immobile time and ambulation counts in the FST and OFT 
tests, respectively. These results agree with a previous report 
from our group (Túnez et al 2007a) and with several other 
studies (Pieper and Newman 1999; Mucignat-Caretta et al 
2006; Breuer et al 2007). 17βE2 administration reversed the 
changes induced by OBX in male Wistar rats. Indirectly, 
these data are in agreement with reports which show that 
estrogens have a clinically signiﬁ  cant antidepressant effect 
in perimenopausal women (Nagata et al 2005; Gryllstrom 
et al 2007; Soares et al 2007) and experimental studies show-
ing that steroid hormones synergize the anxiolytic effect 
prompted by desispramine in rats, suggesting an interaction 
between hormones and antidepressants (Martínez-Mota et al 
2000, 2005). They are also in agreement with data which 
reveal that gonadectomy intensify the effects triggered by 
OBX (Stock et al 2000, 2001).
In addition, we have observed that both behavioral 
disorders prompted by OBX and their restoration to nor-
mality after 17βE2 administration occur concomitantly with 
changes in oxidative stress biomarkers. In this line, Haeser 
Ada and colleagues (2007) found that the drug clonazepam 
reduces the immobility time and improves the oxidative 
status in diabetic rats. Moreover, Khanzode and colleagues 
(2003) found evidence that indicates depression in patients 
with major depression is associated with oxidative stress and 
that this event can be reversed by treatment with ﬂ  uoxetine 
ad citalopram. Likewise, a previous study of our group 
found that OBX triggers depression and oxidative stress, 
whereas treatment with ﬂ  uoxetine reverses the increases in 
the immobility time and hyperactivity towards normality 
(Túnez et al 2007a). Taken together, these results indicate 
that oxidative stress play an important role in etiopathogeny 
of depression and the neuroprotective and antidepressant 
action of 17βE2 may be due, at least partly, to its antioxida-
tive properties.
On basis of our data and the studies by other researchers, 
the modulator effects of 17βE2 on behavioral response fol-
lowing OBX may involve different mechanisms and path-
ways: i) membrane receptor, such as intracellular estrogen 
receptors (ERs).Indeed, the studies performed by Frye’s 
group concluded that estradiol antianxiety and antidepres-
sive effects may involve estrogen receptor beta (ERβ) in the 
hippocampus (Walf and Frye 2005, 2007b); ii) modulation 
hypothalamic-pituitary-adrenal axis (HPA) activity. The 
hippocampus is part of the limbic region which plays an 
important role in the regulation of emotional processing, 
providing inhibitory feedback to the HPA (Stock et al 2000; 
Figueiredo et al 2002, 2003; Walf and Frye 2005); and iii) 
antioxidative effects.
In this work, we have focused in the study of the anti-
oxidative, antidepressant, and antianxiety effect of estrogen 
in OBX-model. In addition, we have tried to establish the 
possible role plays by oxidative stress in the pathogenesis 
of both OBX and indirectly major depression in order to 
evaluate the possible relationship between oxidative stress 
and behavioral changes. This study presents some limits 
which would be interesting to investigate in future work; as 
they are other relevant neurochemistry parameters such as 
serotonin, corticosterone, and estradiol levels in both brain 
tissue and plasma in this experimental model.
Table 1 Changes in the levels of oxidative stress biomarkers
  LPO nmol/mg protein  GSH nmol/mg protein  GSH-Px U/mg protein  SOD U/mg protein
Control 8.12  ± 0.40  6.39 ± 0.09  23.20 ± 1.02  40.40 ± 0.51
17βE2 8.47  ± 0.22  6.60 ± 0.12  22.60 ± 0.51  40.80 ± 0.97
Sham operated 8.80  ± 0.29  6.37 ± 0.10  22.80 ± 0.66  40.40 ± 0.60
OBX 22.75  ± 0.32a  4.16 ± 0.12a 12.80  ± 0.49a 22.20  ± 0.37a
OBX+17βE2 8.29  ± 0.29b  6.76 ± 0.24b 24.75  ± 0.86b 46.00  ± 1.87b
Notes: The results are presented as mean ± SD; n = 5 animals per group.ap  0.001 versus control group; bp  0.001 versus OBX group.Neuropsychiatric Disease and Treatment 2008:4(2) 447
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Figure 2 Effects of OBX and 17βE2 on LDH (panel A) and caspase-3 activity (panel B). Values are mean ± SD, n = 5 animals per group. ap  0.001 versus control group; 
bP  0.001 versus OBX group.
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In summary, our results suggest that 17βE2 exerts an 
antidepressant and antioxidative effect in the OBX model 
of depression. However, further research is required in order 
to better evaluate the mechanisms involved and relationship 
between estrogens, oxidative, and neurochemical changes 
after OBX context that may contribute to the behavioral 
changes observed in this study.
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